|
1
|
Xu Y, Shi F, Zhang Y, Yin M, Han X, Feng J
and Wang G: Twenty-year outcome of prevalence, incidence, mortality
and survival rate in patients with malignant bone tumors. Int J
Cancer. 154:226–240. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xi Y, Qiao L, Na B, Liu H, Zhang S, Zheng
R, Wang W, Sun K, Wei W and He J: Primary malignant bone tumors
incidence, mortality, and trends in China from 2000 to 2015. Chin
Med J (Engl). 136:2037–2043. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
4
|
Cazzato RL, Garnon J, Jennings JW and
Gangi A: Interventional management of malignant bone tumours. J Med
Imaging Radiat Oncol. 67:862–869. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guedes A, Oliveira MBDR, Melo A and Carmo
CCMD: Update in imaging evaluation of bone and soft tissue
sarcomas. Rev Bras Ortop (Sao Paulo). 58:179–190. 2023.PubMed/NCBI
|
|
6
|
Tomasian A, Hillen TJ and Jennings JW:
Bone biopsies: What radiologists need to know. AJR Am J Roentgenol.
215:523–533. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li X, Seebacher NA, Hornicek FJ, Xiao T
and Duan Z: Application of liquid biopsy in bone and soft tissue
sarcomas: Present and future. Cancer Lett. 439:66–77. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Siravegna G, Mussolin B, Venesio T,
Marsoni S, Seoane J, Dive C, Papadopoulos N, Kopetz S, Corcoran RB,
Siu LL and Bardelli A: How liquid biopsies can change clinical
practice in oncology. Ann Oncol. 30:1580–1590. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pantel K, Alix-Panabières C, Hofman P,
Stoecklein NH, Lu YJ, Lianidou E, Giacomini P, Koch C, de Jager V,
Deans ZC, et al: Fostering the implementation of liquid biopsy in
clinical practice: Meeting report 2024 of the European liquid
biopsy society (ELBS). J Exp Clin Cancer Res. 44:1562025.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Takahashi N, Pongor L, Agrawal SP, Shtumpf
M, Gurjar A, Rajapakse VN, Shafiei A, Schultz CW, Kim S, Roame D,
et al: Genomic alterations and transcriptional phenotypes in
circulating free DNA and matched metastatic tumor. Genome Med.
17:152025. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Audinot B, Drubay D, Gaspar N, Mohr A,
Cordero C, Marec-Bérard P, Lervat C, Piperno-Neumann S, Jimenez M,
Mansuy L, et al: ctDNA quantification improves estimation of
outcomes in patients with high-grade osteosarcoma: A translational
study from the OS2006 trial. Ann Oncol. 35:559–568. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cervera ST, Rodríguez-Martín C,
Fernández-Tabanera E, de Mera RM, Morin M, Fernández-Peñalver S,
Iranzo-Martínez M, Amhih-Cardenas J, García-García L,
González-González L, et al: Therapeutic potential of EWSR1-FLI1
inactivation by CRISPR/Cas9 in ewing sarcoma. Cancers (Basel).
13:37832021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mu H, Zuo D, Chen J, Liu Z, Wang Z, Yang
L, Shi Q and Hua Y: Detection and surveillance of circulating tumor
cells in osteosarcoma for predicting therapy response and
prognosis. Cancer Biol Med. 19:1397–1409. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Satelli A, Mitra A, Cutrera JJ, Devarie M,
Xia X, Ingram DR, Dibra D, Somaiah N, Torres KE, Ravi V, et al:
Universal marker and detection tool for human sarcoma circulating
tumor cells. Cancer Res. 74:1645–1650. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu W, Long Q, Zhang W, Zeng D, Hu B, Liu
S and Chen L: miRNA-221-3p derived from M2-polarized
tumor-associated macrophage exosomes aggravates the growth and
metastasis of osteosarcoma through SOCS3/JAK2/STAT3 axis. Aging
(Albany NY). 13:19760–19775. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gally TB, Aleluia MM, Borges GF and Kaneto
CM: Circulating MicroRNAs as novel potential diagnostic biomarkers
for osteosarcoma: A systematic review. Biomolecules. 11:14322021.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu GG, Nafa K, Agaram N, Zehir A, Benayed
R, Sadowska J, Borsu L, Kelly C, Tap WD, Fabbri N, et al: Genomic
profiling identifies association of IDH1/IDH2 mutation with longer
relapse-free and metastasis-free survival in high-grade
chondrosarcoma. Clin Cancer Res. 26:419–427. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Keller L, Belloum Y, Wikman H and Pantel
K: Clinical relevance of blood-based ctDNA analysis: Mutation
detection and beyond. Br J Cancer. 124:345–358. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tashireva LA, Savelieva OE, Grigoryeva ES,
Nikitin YV, Denisov EV, Vtorushin SV, Zavyalova MV, Cherdyntseva NV
and Perelmuter VM: Heterogeneous manifestations of
epithelial-mesenchymal plasticity of circulating tumor cells in
breast cancer patients. Int J Mol Sci. 22:25042021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brooks TG, Lahens NF, Mrčela A and Grant
GR: Challenges and best practices in omics benchmarking. Nat Rev
Genet. 25:326–339. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stejskal P, Goodarzi H, Srovnal J, Hajdúch
M, van Veer LJ and Magbanua MJM: Circulating tumor nucleic acids:
biology, release mechanisms, and clinical relevance. Mol Cancer.
22:152023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sadikovic B and Pare G: Genomics and
epigenomics in pediatric oncology and clinical laboratory genetics.
Clin Biochem. 47:731–732. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kosela-Paterczyk H, Paziewska A, Kulecka
M, Balabas A, Kluska A, Dabrowska M, Piatkowska M, Zeber-Lubecka N,
Ambrozkiewicz F and Karczmarski J: Signatures of circulating
microRNA in four sarcoma subtypes. J Cancer. 11:874–882. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Asano N, Matsuzaki J, Ichikawa M, Kawauchi
J, Takizawa S, Aoki Y, Sakamoto H, Yoshida A, Kobayashi E, Tanzawa
Y, et al: A serum microRNA classifier for the diagnosis of sarcomas
of various histological subtypes. Nat Commun. 10:12992019.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shulman DS, Klega K, Imamovic-Tuco A,
Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL and
Gorlick R: Detection of circulating tumour DNA is associated with
inferior outcomes in Ewing sarcoma and osteosarcoma: A report from
the Children's oncology group. Br J Cancer. 119:615–621. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhu Y, Chen J, Chen C, Tang R, Xu J, Shi S
and Yu X: Deciphering mechanical cues in the microenvironment: From
non-malignant settings to tumor progression. Biomark Res.
13:112025. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ucci A, Rucci N and Ponzetti M: Liquid
biopsies in primary and secondary bone cancers. Cancer Drug Resist.
5:541–559. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Turabi K, Klute K and Radhakrishnan P:
Decoding the dynamics of circulating tumor DNA in liquid biopsies.
Cancers (Basel). 16:24322024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Udomruk S, Phanphaisarn A, Kanthawang T,
Sangphukieo A, Sutthitthasakul S, Tongjai S, Teeyakasem P,
Thongkumkoon P, Orrapin S, Moonmuang S, et al: Characterization of
cell-free DNA size distribution in osteosarcoma patients. Clin
Cancer Res. 29:2085–2094. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bodlak A, Chang K, Channel J, Treece AL,
Donaldson N, Cost CR, Garrington TP, Greffe B, Luna-Fineman S,
Sopfe J, et al: Circulating plasma tumor DNA is superior to plasma
tumor RNA detection in ewing sarcoma patients: ptDNA and ptRNA in
ewing sarcoma. J Mol Diagn. 23:872–881. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mamo T, Mladek AC, Shogren KL, Gustafson
C, Gupta SK, Riester SM, Maran A, Galindo M, van Wijnen AJ,
Sarkaria JN and Yaszemski MJ: Inhibiting DNA-PKCS
radiosensitizes human osteosarcoma cells. Biochem Biophys Res
Commun. 486:307–313. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tsoi KM, Gokgoz N, Darville-O'Quinn P,
Prochazka P, Malekoltojari A, Griffin AM, Ferguson PC, Wunder JS
and Andrulis IL: Detection and utility of cell-free and circulating
tumour DNA in bone and soft-tissue sarcomas. Bone Joint Res.
10:602–610. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Aiyer S, Kim TH, Collier K, Pollock R,
Verschraegen C, Stover DG and Tinoco G: Unlocking the potential of
ctDNA in sarcomas: A review of recent advances. Cancers (Basel).
17:10402025. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen K, Zhao H, Shi Y, Yang F, Wang LT,
Kang G, Nie Y and Wang J: Perioperative dynamic changes in
circulating tumor DNA in patients with lung cancer (DYNAMIC). Clin
Cancer Res. 25:7058–7067. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Murtaza M, Dawson SJ, Tsui DW, Gale D,
Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS,
et al: Non-invasive analysis of acquired resistance to cancer
therapy by sequencing of plasma DNA. Nature. 497:108–112. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tsuda Y, Zhang L, Meyers P, Tap WD, Healey
JH and Antonescu CR: The clinical heterogeneity of round cell
sarcomas with EWSR1/FUS gene fusions: Impact of gene fusion type on
clinical features and outcome. Genes Chromosomes Cancer.
59:525–534. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lianidou E: Detection and relevance of
epigenetic markers on ctDNA: Recent advances and future outlook.
Mol Oncol. 15:1683–1700. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nicolle R, Ayadi M, Gomez-Brouchet A,
Armenoult L, Banneau G, Elarouci N, Tallegas M, Decouvelaere AV,
Aubert S, Rédini F, et al: Integrated molecular characterization of
chondrosarcoma reveals critical determinants of disease
progression. Nat Commun. 10:46222019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Grasset EM, Dunworth M, Sharma G, Loth M,
Tandurella J, Cimino-Mathews A, Gentz M, Bracht S, Haynes M, Fertig
EJ and Ewald AJ: Triple-negative breast cancer metastasis involves
complex epithelial-mesenchymal transition dynamics and requires
vimentin. Sci Transl Med. 14:eabn75712022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hayashi M, Zhu P, McCarty G, Meyer CF,
Pratilas CA, Levin A, Morris CD, Albert CM, Jackson KW, Tang CM and
Loeb DM: Size-based detection of sarcoma circulating tumor cells
and cell clusters. Oncotarget. 8:78965–78977. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xu L, Mao X, Imrali A, Syed F, Mutsvangwa
K, Berney D, Cathcart P, Hines J, Shamash J and Lu YJ: Optimization
and evaluation of a novel size based circulating tumor cell
isolation system. PLoS One. 10:e01380322015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Choo S, Wang P, Newbury R, Roberts W and
Yang J: Reactivation of TWIST1 contributes to Ewing sarcoma
metastasis. Pediatr Blood Cancer. 65:doi:10.1002/pbc.26721. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Crompton BD, Stewart C, Taylor-Weiner A,
Alexe G, Kurek KC, Calicchio ML, Kiezun A, Carter SL, Shukla SA and
Mehta SS: The genomic landscape of pediatric Ewing sarcoma. Cancer
Discov. 4:1326–1341. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Magbanua MJ, Sosa EV, Roy R, Eisenbud LE,
Scott JH, Olshen A, Pinkel D, Rugo HS and Park JW: Genomic
profiling of isolated circulating tumor cells from metastatic
breast cancer patients. Cancer Res. 73:30–40. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Brady SW, Ma X, Bahrami A, Satas G, Wu G,
Newman S, Rusch M, Putnam DK, Mulder HL, Yergeau DA, et al: The
clonal evolution of metastatic osteosarcoma as shaped by cisplatin
treatment. Mol Cancer Res. 17:895–906. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gutteridge A, Rathbone VM, Gibbons R, Bi
M, Archard N, Davies KEJ, Brown J, Plagnol V, Pillay N, Amary F, et
al: Digital PCR analysis of circulating tumor DNA: a biomarker for
chondrosarcoma diagnosis, prognostication, and residual disease
detection. Cancer Med. 6:2194–2202. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Otsuji K, Takahashi Y, Osako T, Kobayashi
T, Takano T, Saeki S, Yang L, Baba S, Kumegawa K and Suzuki H:
Serial single-cell RNA sequencing unveils drug resistance and
metastatic traits in stage IV breast cancer. NPJ Precis Oncol.
8:2222024. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ring A, Nguyen-Sträuli BD, Wicki A and
Aceto N: Biology, vulnerabilities and clinical applications of
circulating tumour cells. Nat Rev Cancer. 23:95–111. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Di Pompo G, Cortini M, Baldini N and Avnet
S: Acid microenvironment in bone sarcomas. Cancers (Basel).
13:131538482021. View Article : Google Scholar
|
|
51
|
Voss TG, Fermin CD, Levy JA, Vigh S, Choi
B and Garry RF: Alteration of intracellular potassium and sodium
concentrations correlates with induction of cytopathic effects by
human immunodeficiency virus. J Virol. 70:5447–5454. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Serpas L, Chan RWY, Jiang P, Ni M, Sun K,
Rashidfarrokhi A, Soni C, Sisirak V, Lee WS, Cheng SH, et al:
Dnase1l3 deletion causes aberrations in length and end-motif
frequencies in plasma DNA. Proc Natl Acad Sci USA. 116:641–649.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Stucker S, Chen J, Watt FE and Kusumbe AP:
Bone angiogenesis and vascular niche remodeling in stress, aging,
and diseases. Front Cell Dev Biol. 8:6022692020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Dalal S, Berry AM, Cullinane CJ, Mangham
DC, Grimer R, Lewis IJ, Johnston C, Laurence V and Burchill SA:
Vascular endothelial growth factor: A therapeutic target for tumors
of the Ewing's sarcoma family. Clin Cancer Res. 11:2364–2378. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kurma K and Alix-Panabières C:
Mechanobiology and survival strategies of circulating tumor cells:
a process towards the invasive and metastatic phenotype. Front Cell
Dev Biol. 11:11884992023. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lee JS, Cho EH, Kim B, Hong J, Kim YG, Kim
Y, Jang JH, Lee ST, Kong SY, Lee W, et al: Clinical practice
guideline for blood-based circulating tumor DNA assays. Ann Lab
Med. 44:195–209. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bettegowda C, Sausen M, Leary RJ, Kinde I,
Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B and Alani RM:
Detection of circulating tumor DNA in early- and late-stage human
malignancies. Sci Transl Med. 6:224ra242014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Siravegna G, Marsoni S, Siena S and
Bardelli A: Integrating liquid biopsies into the management of
cancer. Nat Rev Clin Oncol. 14:531–548. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ammerlaan W and Betsou F: Biospecimen
science of blood for cfDNA genetic analyses. Curr Pathobiol Rep.
7:9–15. 2019. View Article : Google Scholar
|
|
60
|
Diaz IM, Nocon A, Mehnert DH, Fredebohm J,
Diehl F and Holtrup F: Performance of streck cfDNA blood collection
tubes for liquid biopsy testing. PLoS One. 11:e01663542016.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Sathyanarayana SH, Spracklin SB,
Deharvengt SJ, Green DC, Instasi MD, Gallagher TL, Shah PS and
Tsongalis GJ: Standardized workflow and analytical validation of
cell-free DNA extraction for liquid biopsy using a magnetic
bead-based cartridge system. Cells. 14:10622025. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Pittella-Silva F, Chin YM, Chan HT,
Nagayama S, Miyauchi E, Low SK and Nakamura Y: Plasma or serum:
Which is preferable for mutation detection in liquid biopsy? Clin
Chem. 66:946–957. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Andersson D, Kristiansson H, Santamaría
ML, Zafar H, Mijakovic I, Naluai AT and Ståhlberg A: Evaluation of
automatic cell free DNA extraction metrics using different blood
collection tubes. Sci Rep. 15:193642025. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Alikian M, Ellery P, Forbes M, Gerrard G,
Kasperaviciute D, Sosinsky A, Mueller M, Whale AS, Milojkovic D,
Apperley J, et al: Next-generation sequencing-assisted DNA-based
digital PCR for a personalized approach to the detection and
quantification of residual disease in chronic myeloid leukemia
patients. J Mol Diagn. 18:176–189. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Arildsen NS, de la Fuente LM, Måsbäck A,
Malander S, Forslund O, Kannisto P and Hedenfalk I: Detecting TP53
mutations in diagnostic and archival liquid-based Pap samples from
ovarian cancer patients using an ultra-sensitive ddPCR method. Sci
Rep. 9:155062019. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Romero A, Jantus-Lewintre E, García-Peláez
B, Royuela A, Insa A, Cruz P, Collazo A, Altozano JP, Vidal OJ and
Diz P: Comprehensive cross-platform comparison of methods for
non-invasive EGFR mutation testing: Results of the RING
observational trial. Mol Oncol. 15:43–56. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Gradilone A, Iacovelli R, Cortesi E,
Raimondi C, Gianni W, Nicolazzo C, Petracca A, Palazzo A, Longo F,
Frati L and Gazzaniga P: Circulating tumor cells and ‘suspicious
objects’ evaluated through CellSearch® in metastatic
renal cell carcinoma. Anticancer Res. 31:4219–4221. 2011.PubMed/NCBI
|
|
68
|
Cohen EN, Jayachandran G, Hardy MR,
Subramanian AM, Meng X and Reuben JM: Antigen-agnostic
microfluidics-based circulating tumor cell enrichment and
downstream molecular characterization. PLoS One. 15:e02411232020.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Lampignano R, Schneck H, Neumann M, Fehm T
and Neubauer H: Enrichment, isolation and molecular
characterization of EpCAM-negative circulating tumor cells. Adv Exp
Med Biol. 994:181–203. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Benini S, Gamberi G, Cocchi S, Garbetta J,
Alberti L, Righi A, Gambarotti M, Picci P and Ferrari S: Detection
of circulating tumor cells in liquid biopsy from Ewing sarcoma
patients. Cancer Manag Res. 10:49–60. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Machado I, Navarro S, Picci P and
Llombart-Bosch A: The utility of SATB2 immunohistochemical
expression in distinguishing between osteosarcomas and their
malignant bone tumor mimickers, such as Ewing sarcomas and
chondrosarcomas. Pathol Res Pract. 212:811–816. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Conner JR and Hornick JL: SATB2 is a novel
marker of osteoblastic differentiation in bone and soft tissue
tumours. Histopathology. 63:36–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Keppens C, Dequeker EMC, Patton SJ,
Normanno N, Fenizia F, Butler R, Cheetham M, Fairley JA, Williams
H, Hall JA, et al: International pilot external quality assessment
scheme for analysis and reporting of circulating tumour DNA. BMC
Cancer. 18:8042018. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
van Dessel LF, Vitale SR, Helmijr JCA,
Wilting SM, van der Vlugt-Daane M, Oomen-de Hoop E, Sleijfer S,
Martens JWM, Jansen MPHM and Lolkema MP: High-throughput isolation
of circulating tumor DNA: A comparison of automated platforms. Mol
Oncol. 13:392–402. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Geeurickx E and Hendrix A: Targets,
pitfalls and reference materials for liquid biopsy tests in cancer
diagnostics. Mol Aspects Med. 72:1008282020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Risberg B, Tsui DWY, Biggs H, de Almagro
ARV, Dawson SJ, Hodgkin C, Jones L, Parkinson C, Piskorz A, Marass
F, et al: Effects of collection and processing procedures on plasma
circulating cell-free DNA from cancer patients. J Mol Diagn.
20:883–892. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Deans ZC, Butler R, Cheetham M, Dequeker
EMC, Fairley JA, Fenizia F, Hall JA, Keppens C, Normanno N,
Schuuring E and Patton SJ: IQN path ASBL report from the first
European cfDNA consensus meeting: expert opinion on the minimal
requirements for clinical ctDNA testing. Virchows Arch.
474:681–689. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
van Dessel LF, Beije N, Helmijr JC, Vitale
SR, Kraan J, Look MP, de Wit R, Sleijfer S, Jansen MP, Martens JW
and Lolkema MP: Application of circulating tumor DNA in prospective
clinical oncology trials-standardization of preanalytical
conditions. Mol Oncol. 11:295–304. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Krumbholz M, Eiblwieser J, Ranft A, Zierk
J, Schmidkonz C, Stütz AM, Peneder P, Tomazou EM, Agaimy A, Bäuerle
T, et al: Quantification of translocation-specific ctDNA provides
an integrating parameter for early assessment of treatment response
and risk stratification in ewing sarcoma. Clin Cancer Res.
27:5922–5930. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Lyskjaer I, Davies C, Strobl AC, Hindley
J, James S, Lalam RK, Cross W, Hide G, Rankin KS, Jeys L, et al:
Circulating tumour DNA is a promising biomarker for risk
stratification of central chondrosarcoma with IDH1/2 and GNAS
mutations. Mol Oncol. 15:3679–3690. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Shukla NN, Patel JA, Magnan H, Zehir A,
You D, Tang J, Meng F, Samoila A, Slotkin EK, Ambati SR, et al:
Plasma DNA-based molecular diagnosis, prognostication, and
monitoring of patients with EWSR1 fusion-positive sarcomas. JCO
Precis Oncol. 2017.PO.16.00028. 2017. View Article : Google Scholar
|
|
82
|
Lyskjær I, Kara N, De Noon S, Davies C,
Rocha AM, Strobl AC, Usher I, Gerrand C, Strauss SJ, Schrimpf D, et
al: Osteosarcoma: Novel prognostic biomarkers using circulating and
cell-free tumour DNA. Eur J Cancer. 168:1–11. 2022. View Article : Google Scholar
|
|
83
|
Van Paemel R, Vandeputte C, Raman L, Van
Thorre J, Willems L, Van Dorpe J, Van Der Linden M, De Wilde J, De
Koker A, Menten B, et al: The feasibility of using liquid biopsies
as a complementary assay for copy number aberration profiling in
routinely collected paediatric cancer patient samples. Eur J
Cancer. 160:12–23. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Zhang H, Gao P, Xiao X, Heger M, Geng L,
Fan B, Yuan Y, Huang C, Chen G, Liu Y, et al: A liquid biopsy-based
method for the detection and quantification of circulating tumor
cells in surgical osteosarcoma patients. Int J Oncol. 50:1075–1086.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Furukawa N, Hasegawa N, Kubota D, Nakamura
Y, Tanaka H, Iwata S, Kawai A, Saito T, Takagi T, Kohsaka S and
Ishijima M: Prognostic potential of fusion gene analysis using
plasma cell-free RNA in malignant bone and soft tissue tumours. BMC
Cancer. 25:5872025. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Christodoulou E, Yellapantula V,
O'Halloran K, Xu L, Berry JL, Cotter JA, Zdanowicz A, Mascarenhas
L, Amatruda JF, Ostrow D, et al: Combined low-pass whole genome and
targeted sequencing in liquid biopsies for pediatric solid tumors.
NPJ Precis Oncol. 7:212023. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Benje M, Vitacchio T, Fritsche D and
Tinganelli W: Gene expression profiling and phenotypic
characterization of circulating tumor cells derived from a murine
osteosarcoma model. Cancers (Basel). 17:12102025. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Li M, Lu Y, Long Z, Li M, Kong J, Chen G
and Wang Z: Prognostic and clinicopathological significance of
circulating tumor cells in osteosarcoma. J Bone Oncol.
16:1002362019. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Fujiwara T, Uotani K, Yoshida A, Morita T,
Nezu Y, Kobayashi E, Yoshida A, Uehara T, Omori T, Sugiu K, et al:
Clinical significance of circulating miR-25-3p as a novel
diagnostic and prognostic biomarker in osteosarcoma. Oncotarget.
8:33375–33392. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Li Q, Song S, Ni G, Li Y and Wang X: Serum
miR-542-3p as a prognostic biomarker in osteosarcoma. Cancer
Biomark. 21:521–526. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Heishima K, Meuten T, Yoshida K, Mori T
and Thamm DH: Prognostic significance of circulating microRNA-214
and −126 in dogs with appendicular osteosarcoma receiving
amputation and chemotherapy. BMC Vet Res. 15:392019. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Georges S, Calleja LR, Jacques C, Lavaud
M, Moukengue B, Lecanda F, Quillard T, Gabriel MT, Cartron PF,
Baud'huin M, et al: Loss of miR-198 and −206 during primary tumor
progression enables metastatic dissemination in human osteosarcoma.
Oncotarget. 9:35726–35741. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Dhir A, Hayashi M, Bodlak A, Oesterheld J,
Loeb DM, Mascarenhas L, Isakoff MS, Sandler ES, Borinstein SC,
Trucco M, et al: Phase II trial of gemcitabine and nab-paclitaxel
for recurrent osteosarcoma with serial monitoring using liquid
biopsy: A report from the national pediatric cancer foundation.
Clin Cancer Res. 30:5314–5322. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Green D, van Ewijk R, Tirtei E, Andreou D,
Baecklund F, Baumhoer D, Bielack SS, Botchu R, Boye K, Brennan B,
et al: Biological sample collection to advance research and
treatment: A fight osteosarcoma through european research and euro
ewing consortium statement. Clin Cancer Res. 30:3395–3406. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Fu Y, Xu Y, Liu W, Zhang J, Wang F, Jian
Q, Huang G, Zou C, Xie X, Kim AH, et al: Tumor-informed deep
sequencing of ctDNA detects minimal residual disease and predicts
relapse in osteosarcoma. EClinicalMedicine. 73:1026972024.
View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Goodspeed A, Bodlak A, Duffy AB,
Nelson-Taylor S, Oike N, Porfilio T, Shirai R, Walker D, Treece A,
Black J, et al: Single-Cell RNA sequencing of ewing sarcoma tumors
demonstrates transcriptional heterogeneity and clonal evolution.
Clin Cancer Res. 31:2010–2023. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Seidel MG, Kashofer K, Moser T, Thueringer
A, Liegl-Atzwanger B, Leithner A, Szkandera J, Benesch M,
El-Heliebi A and Heitzer E: Clinical implementation of plasma
cell-free circulating tumor DNA quantification by digital droplet
PCR for the monitoring of Ewing sarcoma in children and
adolescents. Front Pediatr. 10:9264052022. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J,
Sun T and Wei J: Liquid biopsy in cancer: Current status,
challenges and future prospects. Signal Transduct Target Ther.
9:3362024. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Yang W, Nguyen R, Safri F, Shiddiky MJA,
Warkiani ME, George J and Qiao L: Liquid biopsy in hepatocellular
carcinoma: ctDNA as a potential biomarker for diagnosis and
prognosis. Curr Oncol Rep. 27:791–802. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Ge Q, Zhang ZY, Li SN, Ma JQ and Zhao Z:
Liquid biopsy: Comprehensive overview of circulating tumor DNA
(Review). Oncol Lett. 28:5482024. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Coppola CA, De Summa S, Matera G, Pilato
B, Traversa D and Tommasi S: Liquid Biopsy: The challenges of a
revolutionary approach in oncology. Int J Mol Sci. 26:50132025.
View Article : Google Scholar : PubMed/NCBI
|
